Approved indications
Gimoti is FDA‑approved for adults with diabetic gastroparesis to treat acute and recurrent nausea and vomiting when oral metoclopramide is not tolerated or not effective enough.

Off‑label uses
Clinicians may occasionally consider nasal metoclopramide off label for other causes of gastroparesis‑related nausea when an intranasal route is preferred, but evidence is limited compared with established oral or injectable metoclopramide.

Efficacy expectations
Symptom relief from nausea may begin within hours to a few days of starting therapy, with improved stomach emptying and reduction in vomiting episodes over several days to weeks. In studies, intranasal metoclopramide provided symptom improvement similar to oral metoclopramide while offering an option for patients who have difficulty taking or absorbing oral medication. As with all prokinetic therapies, some patients experience substantial relief while others have only partial benefit, and treatment duration is generally limited due to safety concerns with longer‑term metoclopramide use.

Typical dosing and how to take
For adults, the usual dose is one spray (15 mg) into one nostril four times a day: 30 minutes before each of the three main meals and at bedtime. Before first use, prime the spray as directed in the instructions; gently blow the nose, insert the tip into one nostril, keep the head upright, and press the pump while sniffing gently. Do not exceed the recommended number of doses or use longer than 8 weeks unless specifically directed.

Special dosing instructions
Dose reductions may be needed in patients with kidney or liver problems or in older adults. If nasal congestion significantly interferes with absorption, a healthcare provider may adjust treatment. The same nostril can be used for all doses unless otherwise instructed.

Missed dose
If a dose is missed, take it as soon as remembered unless it is almost time for the next scheduled dose; if it is close to the next dose, skip the missed dose and resume the regular schedule, without doubling doses.

Overdose
In case of overdose, symptoms may include severe drowsiness, confusion, agitation, or abnormal movements; seek emergency medical care or call a poison control center immediately.

Common side effects
Common side effects include altered taste, nasal irritation or discomfort, headache, fatigue, restlessness, and gastrointestinal changes such as diarrhea; these are usually mild to moderate and may appear soon after dosing.

Serious or rare adverse effects
Serious neurologic reactions can occur, including acute dystonic reactions (muscle spasms, neck or eye twisting), tardive dyskinesia (involuntary movements of the face, tongue, or limbs, which may be irreversible), Parkinson‑like symptoms, and neuroleptic malignant syndrome (fever, stiff muscles, confusion). Other serious reactions include depression or suicidal thoughts, allergic reactions, and significant changes in blood pressure or heart rhythm; any of these require immediate medical attention.

Warnings and precautions
Gimoti carries a boxed warning for tardive dyskinesia, with risk increasing with total duration and cumulative dose; therapy should generally not exceed 8 weeks. It is usually avoided in patients with a history of tardive dyskinesia or other serious movement disorders, seizure disorders, pheochromocytoma, gastrointestinal bleeding or obstruction, or when stimulation of GI motility is dangerous. Use in pregnancy only if clearly needed; metoclopramide has been used in pregnancy but should still be weighed against risks. Caution is advised during breastfeeding because the drug is excreted into breast milk and can increase prolactin; infants should be monitored if exposure occurs. Dose adjustment and careful monitoring may be needed in kidney or liver impairment and in older adults, who have a higher risk of movement disorders.

Relative safety compared with other options
Like all metoclopramide products, Gimoti has a higher risk of movement‑related adverse effects than many alternative anti‑nausea drugs, which is why it is typically used for specific indications and limited durations rather than for general or long‑term nausea.

Reporting and safety updates
Patients can report side effects to their healthcare provider, to the product’s manufacturer, or directly to the FDA MedWatch program, and can check FDA and manufacturer websites for updated safety communications.

Drug and other interactions
Gimoti (metoclopramide) can interact with other drugs that affect dopamine or serotonin (such as antipsychotics, some antidepressants), increasing the risk of movement disorders or serotonin syndrome. It may alter the absorption of oral medicines by speeding stomach emptying, potentially changing effects of drugs like certain diabetes medicines or pain medicines. Sedatives, opioids, and alcohol can increase drowsiness or dizziness. Strong CYP2D6 inhibitors and other agents that affect metoclopramide metabolism or transport may change its levels. Always review all prescription medicines, over‑the‑counter drugs, and supplements with a healthcare provider.

Food, alcohol, and procedure interactions
Gimoti is usually given before meals to coordinate with food intake; no specific food is prohibited, but alcohol should be limited or avoided because it can worsen drowsiness and impair judgment. Metoclopramide may be used to aid some GI procedures by promoting emptying, but other diagnostic imaging that relies on normal GI motility may be affected; clinicians adjust timing accordingly.

Precautions and monitoring
Use with caution or avoid in patients with a history of movement disorders, Parkinson’s disease, seizure disorders, significant depression, pheochromocytoma, or conditions where increased GI motility is risky (such as GI bleeding or perforation). Monitoring for new or worsening involuntary movements, mood changes, and symptoms of neuroleptic malignant syndrome is important, especially early in therapy and with dose changes. In patients with kidney or liver impairment or in older adults, clinicians may monitor more closely and use lower doses.

Q: What is Gimoti used for?
A: Gimoti is a nasal spray form of metoclopramide used in adults to treat nausea and vomiting associated with diabetic gastroparesis.

Q: How quickly does Gimoti start working?
A: Some people notice nausea relief within hours to a few days, but full improvement in gastroparesis symptoms may take several days to a few weeks of regular dosing.

Q: How long can I use Gimoti?
A: Because of the risk of movement disorders such as tardive dyskinesia, treatment with Gimoti or any metoclopramide product is generally limited to no more than 8 weeks unless your clinician decides otherwise.

Q: Can I use Gimoti with my other medications?
A: Many people can take Gimoti with other medicines, but it can interact with certain drugs and change how some oral medications are absorbed, so your healthcare provider and pharmacist should review all of your prescriptions, over‑the‑counter medicines, and supplements.

Q: What serious side effects should I watch for?
A: Contact a healthcare professional right away if you develop uncontrolled or unusual movements of the face, tongue, or limbs, muscle stiffness, high fever, severe confusion, very low or high mood, or signs of an allergic reaction such as trouble breathing or swelling of the face or throat.

Storage
Store Gimoti nasal spray at room temperature, away from excess heat, moisture, and light, and keep the bottle tightly closed and out of reach of children.

Disposal
Do not use the spray after the expiration date; dispose of used or expired bottles in household trash out of reach of children and pets, or follow any local take‑back or pharmacy disposal programs if available.